ArticleOncology letters2016
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study.The oncologist · 2023Trial
- Incidence of malignant transformation in giant cell tumor of bone following denosumab therapy: a systematic review and meta-analysis.Journal of bone oncology · 2026Review
- Denosumab regimens in the treatment of giant cell tumor of bone: A systematic review with meta-analysis.World journal of orthopedics · 2025Article
- Review
- Giant Cell Tumor of Soft Tissue: An Updated Review.Journal of clinical medicine · 2024Review
- Article
- The Role of Denosumab in the Treatment of Primary Tumors of Bone.The Journal of hand surgery · 2023Review
- Complications and prognosis of primary thoracic and lumbar giant cell tumors treated by total tumor resection.BMC musculoskeletal disorders · 2023Article
- Review
- Review
- Role of cancer stem cells in the development of giant cell tumor of bone.Cancer cell international · 2020Review
- The Efficacy of Denosumab in the Management of a Tibial Paediatric Aneurysmal Bone Cyst Compromised by Rebound Hypercalcaemia.Case reports in pediatrics · 2020Article
- Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.Current opinion in oncology · 2019Review
- Denosumab Therapy in the Management of Aneurysmal Bone Cysts: A Comprehensive Literature Review.Cureus · 2019Review
- Effect of bisphosphonates on local recurrence of giant cell tumor of bone: a meta-analysis.Cancer management and research · 2019Article
- Review
- Nucleoside diphosphate kinase B promotes osteosarcoma proliferation through c-Myc.Cancer biology & therapy · 2018Article
- Left orbital roof giant cell tumor of bone: A case report.Surgical neurology international · 2018Article
- Giant cell tumour of the distal radius/ulna: response to pre-operative treatment with short-term denosumab.Clinical sarcoma research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive tumor that rarely metastasizes and typically occurs in the bones. At present, the primary treatment for GCTB is curettage with local adjuvants. Giant cells express receptor activator of nuclear factor-κB ligand (RANKL). Denosumab, a RANKL inhibitor appears to present an effective therapeutic option in advanced cases of GCTB. The aim of the present study was to confirm the efficacy of denosumab in large group of patients with locally advanced GCTB. A total of 35 patients with histologically confirmed GCTB that were treated with denosumab with no participation in clinical trials between May 2013 and September 2015 were included in the present study. Denosumab treatment was administered until complete tumor resection was feasible or tumor progression or unacceptable toxicity had occurred. The mean denosumab treatment duration was 7.4 months. A total of 17 patients received surgery following denosumab treatment: 11 patients underwent wide en bloc resection with prosthesis implantation in 10 cases and 6 patients were treated with intralesional curettage. Tumor progression was observed in 2 patients that underwent intralesional curettage without prosthesis implantation. In addition, tumor progression was observed during denosumab treatment in 2 patients that had previously undergone radiotherapy. The overall 1-year progression-free survival rate was 92.8%. Thus, for patients with advanced, unresectable, progressive or symptomatic pretreated GCTB, denosumab provides a therapeutic option not previously available, which has become the standard therapy in multidisciplinary management of GCTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.